[CAS NO. 222638-67-7] BEChydrochloride

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [222638-67-7]

Catalog

HY-19548A

Brand

MCE

CAS

222638-67-7

DESCRIPTION [222638-67-7]

Overview

MDL	MFCD03453539
Molecular Weight	229.49
Molecular Formula	C5H13BClNO4S
SMILES	N[C@@H](CSCCB(O)O)C(O)=O.[H]Cl

For research use only. We do not sell to patients.

Summary

BEC hydrochloride is a slow-binding and competitive Arginase II inhibitor with K _i of 0.31 μM and 30 nM at pH 7.5 and pH 9.5, respectively ^[1] .

IC50 & Target

Ki: 0.31 μM (BEC hydrochloride, at pH 7.5) and 30 nM (BEC hydrochloride, at pH 9.5) ^[1]

In Vitro

The X-ray crystal structure of the arginase-BEC complex has been determined at 2.3 Å resolution from crystals perfectly twinned by hemihedry. The structure of the complex reveals that the boronic acid moiety undergoes nucleophilic attack by metal-bridging hydroxide ion to yield a tetrahedral boronate anion that bridges the binuclear manganese cluster, thereby mimicking the tetrahedral intermediate (and its flanking transition states) in the arginine hydrolysis reaction ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Administration of the arginase inhibitor BEC decreases arginase activity and causes alterations in NO homeostasis, which are reflected by increases in S-nitrosylated and nitrated proteins in the lungs from inflamed mice. BEC enhances perivascular and peribronchiolar lung inflammation, mucus metaplasia, NF-κB DNA binding, and mRNA expression of the NF-κB-driven chemokine genes CCL20 and KC, and leads to further increases in airways hyperresponsiveness ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6J wild-type mice, mice deficient in arginase 2 (Arg2 ^-/- ), mice deficient in both arginase 1 and 2 (Arg1 ^-/- Arg2 ^-/- ), and mice deficient in NOX2 (NOX2 ^-/-
Dosage:	20 mg/kg.
Administration:	I.V., in 0.9% saline, 1 hour before the injection of LPS.
Result:	BEC robustly reduced VEGF expression in neuroglia (72% reduction) and macrophage/microglia (87% reduction).

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL ( 217.87 mM ; Need ultrasonic)

H ₂ O : 5 mg/mL ( 21.79 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.3575 mL	21.7874 mL	43.5749 mL
5 mM	0.8715 mL	4.3575 mL	8.7150 mL
10 mM	0.4357 mL	2.1787 mL	4.3575 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 140 mg/mL (610.05 mM); Clear solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (10.89 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (10.89 mM); Clear solution
4.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (10.89 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

L-Cysteine, S-(2-boronoethyl)-, hydrochloride (1:1)

L-Cysteine, S-(2-boronoethyl)-, hydrochloride

BEC hydrochloride